Healthcare bearish Stocks: Corcept Therapeutics Incorporated (NASDAQ:CORT), ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC), OXiGENE Inc (NASDAQ:OXGN), Depomed Inc (NASDAQ:DEPO)

Corcept Therapeutics, Inc. (NASDAQ:CORT) entered into a manufacturing agreement (the “Agreement”) with AAIPharma Services Corp. (“AAI”), pursuant to which AAI will manufacture and package Korlym® tablets (the “product”). AAI will manufacture the product in accordance with FDA and other regulatory requirements. Corcept Therapeutics Incorporated (NASDAQ:CORT) stock performance was -6.85% in last session and finished the day at $3.40. Traded volume was million shares in the last session and the average volume of the stock remained 555.10K shares. The beta of the stock remained 1.20. Corcept Therapeutics Incorporated (NASDAQ:CORT) insider ownership is 0.50%.

ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) used overall survival as the primary endpoint for a recently completed phase II study of its brain cancer vaccine ICT-107 based on feedback from the FDA. ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) dropped -5.00 percent to $1.14 Tuesday on volume of 1.44million shares. The intra-day range of the stock was $1.05 to $1.22. ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) has a market capitalization of $65.62million.

OXiGENE, Inc. (NASDAQ:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, today announced results from three preclinical studies related to its ongoing research and development programs. The data are being presented this week at the Annual Meeting of the American Association for Cancer Research (AACR) in San Diego, California. OXiGENE Inc (NASDAQ:OXGN)’s stock on Apr 15, 2014 reported a decrease of -7.51% to the closing price of $2.71. Its fifty two weeks range is $1.96 -$5.40. The total market capitalization recorded $41.29million. The overall volume in the last trading session was 1.45million shares. In its share capital, OXGN has 15.25million outstanding shares.

Cadila Healthcare and Zydus Pharmaceuticals said they had entered into a settlement agreement with Depomed Inc (NASDAQ:DEPO) in a patent infringement row. Cadila Healthcare and Zydus Pharmaceuticals today announced in a joint statement that “they have entered into a settlement agreement with Depomed Inc (NASDAQ:DEPO)” regarding the patent infringement litigation related to Gralise 300mg and 600mg tablets. On Tuesday, shares of Depomed Inc (NASDAQ:DEPO) dropped -5.61% to close the day at $12.29. Company return on investment (ROI) is 32.30% and its monthly performance is recorded as -15.07%. Depomed Inc (NASDAQ:DEPO) quarterly revenue growth is 7.90%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone